Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis
Author:
Affiliation:
1. Section of Dermatology and Venereology Department of Medicine University of Verona Verona Italy
2. Dermatology Unit Department of Medicine University of Padua Padua Italy
Publisher
Wiley
Subject
Dermatology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.18015
Reference18 articles.
1. Secukinumab in the treatment of psoriasis: patient selection and perspectives;Yang EJ;Psoriasis (Auckl),2018
2. European Medicines Agency.Cosentyx. Available at:https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx(last accessed 25 April 2019).
3. Secukinumab in plaque psoriasis‐results of two phase 3 trials;Langley RG;N Engl J Med,2014
4. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial;Thaçi D;J Am Acad Dermatol,2015
5. Treatment of patients with plaque psoriasis with secukinumab in a real‐life setting: a 52‐week, multicenter, retrospective study in Spain;Notario J;J Dermatolog Treat,2018
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting;International Journal of Dermatology;2024-01-02
2. Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors;European Journal of Hospital Pharmacy;2023-04-24
3. Real‐world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety;Dermatologic Therapy;2022-11-16
4. Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks;Dermatologic Therapy;2022-10-17
5. On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study;Journal of Dermatological Treatment;2022-06-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3